Last reviewed · How we verify

NCT07065227

Potential Benefits of Sonic Augmentation Technology in Music

Suspended NA Last updated 28 October 2025
What this trial tests

NA trial testing Augmented Theme in Biobehavioral State in 36 participants. Suspended.

Timeline
24 September 2025
Primary endpoint
10 May 2026
10 May 2026

Quick facts

Lead sponsorUniversity of Florida
PhaseNA
StatusSuspended
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment36
Start date24 September 2025
Primary completion10 May 2026
Estimated completion10 May 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Florida

Who can join

Adults 18 to 89, any sex, with Biobehavioral State or Sonic Augmentation Technology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to explore possible benefits and mechanisms through which listening to music enhanced with Sonic Augmentation Technology (SAT) can improve health and wellness. The main goals of the study are: * To examine the immediate effects of listening to the augmented music. * To identify individual characteristics that influence the immediate effects of listening to the augmented music. Participants will: * Complete the online pre- and post-surveys. * Provide pre- and post- music saliva samples (1.5mL). * Listen to the full 15-minutes music session via over-ear headphones.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Augmented Theme

Trials testing the same drug.

Other University of Florida trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07065227.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing